Ocuphire Pharma, Inc.

OCUP

US67577R1023

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
1.85 ^USD	+12.80%		+20.52%	-38.54%

Apr. 11	Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	MT
Apr. 11	Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	CI

Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

March 08, 2024 at 08:22 am EST

Ocuphire Pharma, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 4.8 million compared to net income of USD 33.94 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to basic earnings per share from continuing operations of USD 1.63 a year ago. Diluted loss per share from continuing operations was USD 0.21 compared to diluted earnings per share from continuing operations of USD 1.58 a year ago.
For the full year, net loss was USD 9.99 million compared to net income of USD 17.89 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to basic earnings per share from continuing operations of USD 0.9 a year ago. Diluted loss per share from continuing operations was USD 0.46 compared to diluted earnings per share from continuing operations of USD 0.87 a year ago.

Latest news about Ocuphire Pharma, Inc.

Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	Apr. 11	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	Apr. 11	CI
Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating	Mar. 20	MT
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 08	CI
Ocuphire Pharma Appoints CFO, Science Chief	Feb. 14	MT
Ocuphire Pharma, Inc. Announces Appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer	Feb. 14	CI
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer	Feb. 14	CI
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy	Feb. 05	CI
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions	Jan. 04	CI
Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023	Dec. 06	CI
Transcript : Ocuphire Pharma, Inc., Q3 2023 Earnings Call, Dec 05, 2023	Dec. 05
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer	Nov. 27	CI
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Ocuphire Pharma, Inc. Announces Successful End-Of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy	Nov. 02	CI
Ocuphire Pharma Appoints George Magrath as Chief Executive	Nov. 01	MT
Ocuphire Pharma, Inc. Appoints George Magrath as Member of Board of Directors	Nov. 01	CI
Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes	Nov. 01	CI
Viatris, Ocuphire Pharma Say US FDA Approves Eye Drops to Treat Pharmacologically-Induced Dilation of Pupils	23-09-27	MT
Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops	23-09-27	DJ
Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl?? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents	23-09-27	CI
Ocuphire Pharma Gets FDA Approval for Ryzumvi Opthlamic Solution, FDA Website Shows	23-09-26	MT
Ocuphire Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Ocuphire Pharma, Inc. announced that it expects to receive $50 million in funding from Lincoln Park Capital, LLC	23-08-09	CI
North American Morning Briefing : Investors Await -2-	23-08-07	DJ

Chart Ocuphire Pharma, Inc.

Duration

Period

More charts

Company Profile

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Companyâs lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1Î± and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Companyâs pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ocuphire Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.85 USD

Average target price

19.5 USD

Spread / Average Target

+954.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OCUPHIRE PHARMA, INC.	-38.54%	42M
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B

Other Pharmaceuticals